# A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer

> **NCT00068380** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 17 (actual)

## Conditions studied

- Recurrent Gastric Cancer
- Stage IV Gastric Cancer

## Interventions

- **DRUG:** imatinib mesylate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00068380
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2018-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00068380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00068380, "A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00068380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*